Lactoferrin Treatment in HIV Patients
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 10/20/2018 |
| Start Date: | September 2014 |
| End Date: | January 2018 |
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin
(1500mg bid) for reducing inflammation among HIV positive participants.
(1500mg bid) for reducing inflammation among HIV positive participants.
Inclusion Criteria:
1. HIV-positive participants receiving Antiretroviral Therapy (ART) for >1 year
2. HIV RNA level <200 copies/mL for at least 6 months (≥2 separate values)
3. Age >40 years
Exclusion Criteria:
1. Prior cardiovascular disease or stroke
2. Diabetes
3. Rheumatologic Diseases
4. Pregnancy
5. Chronic kidney disease, stage IV or V (creatinine clearance <30 mL/min/1.73m2)
6. Cirrhosis or end-stage liver disease
We found this trial at
1
site
Click here to add this to my saved trials
